Expressed in the yeast Saccharomyces cerevisiae, human ERK5 is a client of the Hsp90 chaperone that complements loss of the Slt2p (Mpk1p) cell integrity stress-activated protein kinase by Truman, Andrew W et al.
EUKARYOTIC CELL, Nov. 2006, p. 1914–1924 Vol. 5, No. 11
1535-9778/06/$08.000 doi:10.1128/EC.00263-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Expressed in the Yeast Saccharomyces cerevisiae, Human ERK5 Is a
Client of the Hsp90 Chaperone That Complements Loss of the
Slt2p (Mpk1p) Cell Integrity Stress-Activated Protein Kinase
Andrew W. Truman,1 Stefan H. Millson,1 James M. Nuttall,1 Victoria King,1 Mehdi Mollapour,1
Chrisostomos Prodromou,2 Laurence H. Pearl,2 and Peter W. Piper1*
Department of Molecular Biology and Biotechnology, The University of Sheffield, Firth Court, Western Bank, Sheffield S10 2TN,1
and Section for Structural Biology, Institute for Cancer Research, Chester Beatty Laboratories, 237 Fulham Road,
London SW3 6JB,2 United Kingdom
Received 14 August 2006/Accepted 15 August 2006
ERK5 is a mitogen-activated protein (MAP) kinase regulated in human cells by diverse mitogens and
stresses but also suspected of mediating the effects of a number of oncogenes. Its expression in the slt2
Saccharomyces cerevisiae mutant rescued several of the phenotypes caused by the lack of Slt2p (Mpk1p) cell
integrity MAP kinase. ERK5 is able to provide this cell integrity MAP kinase function in yeast, as it is activated
by the cell integrity signaling cascade that normally activates Slt2p and, in its active form, able to stimulate
at least one key Slt2p target (Rlm1p, the major transcriptional regulator of cell wall genes). In vitro ERK5
kinase activity was abolished by Hsp90 inhibition. ERK5 activity in vivo was also lost in a strain that expresses
a mutant Hsp90 chaperone. Therefore, human ERK5 expressed in yeast is an Hsp90 client, despite the widely
held belief that the protein kinases of the MAP kinase class are non-Hsp90-dependent activities. Two-hybrid
and protein binding studies revealed that strong association of Hsp90 with ERK5 requires the dual phosphor-
ylation of the TEY motif in the MAP kinase activation loop. These phosphorylations, at positions adjacent to
the Hsp90-binding surface recently identified for a number of protein kinases, may cause a localized rear-
rangement of this MAP kinase region that leads to creation of the Hsp90-binding surface. Complementation
of the slt2 yeast defect by ERK5 expression establishes a new tool with which to screen for novel agonists and
antagonists of ERK5 signaling as well as for isolating mutant forms of ERK5.
Mitogen-activated protein kinase (MAPK) modules consist
of 3 protein kinases that stimulate each other in series
(MAP3K3MAP2K3MAPK), resulting in the activation of
the terminal and often multifunctional MAPK. These signaling
cascades are key components of the highly interactive protein
kinase networks in eukaryotic cells. As their name implies,
some MAPKs initiate a proliferative response. Others control
pathways of embryogenesis, differentiation, stress responses,
and cell death (42). Association of MAPK modules with scaf-
fold proteins appears to be one way of ensuring that each
MAPK only becomes activated in response to the correct ex-
tracellular stimuli or stress signals (52). Once activated, this
MAPK can then proceed to phosphorylate its substrates, the
latter being often involved in both short-term and longer-term
(e.g., transcription-mediated) cellular changes. Many MAPKs
have substrates in both the cytoplasm and the nucleus, such
that nuclear import/export mechanisms frequently govern their
accessibility to their substrates. The final outcome of any
MAPK activation event is presumably dictated by this sub-
strate availability in any given cell type, by an intrinsic substrate
specificity directed by the docking interaction of the MAPK
with its substrates, and by signal attenuation. The latter in-
volves the intervention of the protein phosphatases that, by
dephosphorylating and thereby deactivating the MAPK, mod-
ulate both the intensity and the duration of the activation
signal.
Mammalian systems possess at least four MAPK subfami-
lies: extracellular-regulated protein kinases 1 and 2 (ERK1/2),
ERK5, c-Jun NH2-terminal protein kinases (JNKs), and p38s.
All are activated in response to the dual Thr/Tyr phosphory-
lation of a Thr-X-Tyr (TXY) motif (X corresponding to a Glu
in ERKs, a Pro in JNK, and a Gly in p38). This TXY phos-
phorylation is catalyzed by the appropriate MAP2K, an en-
zyme that is often in physical interaction with its MAPK sub-
strate, at least until it can activate the latter. Gene knockout
experiments with mice have revealed that these different
MAPK subfamilies mediate different biological responses. The
ERK subfamilies are mostly associated with cell proliferation
and survival, whereas JNKs and p38s are activated mainly in
response to cytokines and stress, being important for patho-
genesis and apoptosis (42). The least studied of these MAPK
subfamilies was, until recently, ERK5. This is a MAPK acti-
vated in response to a variety of signals, including chemical
activators (e.g., serum, epidermal, and nerve growth factors,
lysophosphatidic acid, and phorbol esters), oxidative stress
(e.g., hydrogen peroxide and UV radiation), and physical stress
(e.g., sorbitol, vascular shear stress, and ischemia) (1, 60).
Recently ERK5 has become the subject of intense interest
following the discovery that it is essential for cardiovascular
development and an important contributor to cell survival
mechanisms. ERK5-null mice display defective endothelial cell
morphology, blood vessel formation, and cardiac development,
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leading to embryonic lethality (18). ERK5 activation has been
found to prevent endothelial cell apoptosis by stimulating
phosphorylation of Bad in the cytoplasm and thereby inhibiting
caspase-3 activity (43). Moreover, analysis of human tumors
has revealed a link between abnormal levels of ERK5 expres-
sion and cancer, leading to the suspicion that ERK5 signaling
may be important for mediating the effects of several onco-
genes (see references 19 and 56 for reviews).
Appreciation of the full importance of ERK5 has been rel-
atively slow in coming. This is due, at least in part, to the lack
of biological tools, such as antibodies, specific inhibitors of
ERK5 signaling, and systems to unravel this MAPK geneti-
cally. To this end, we have investigated the functionality of
ERK5 in the Saccharomyces cerevisiae system. So extensive is
the sequence conservation among MAPKs of different species
that the expression of a mammalian MAPK in yeast will often
rescue a defect in one the yeast MAPKs (all of which are
nonessential for growth). For example, Hog1p, the MAPK of
the yeast high osmolarity glycerol pathway can be functionally
replaced by either JNKs (13) or p38 (17). Also, an activated
human ERK1 expressed in yeast partially mimics the active
form of the native Kss1p, though it is unresponsive to the
endogenous activators of this Kss1p (3). In this study, we dem-
onstrate that human ERK5 expression in yeast complements
the lack of Slt2p (Mpk1p), the stress-activated MAPK of the
cell integrity signaling pathway. ERK5 is able to confer this
Slt2p function as it becomes activated in yeast by the MAP2K
activator of Slt2p and, once activated, is able to stimulate at
least one major Slt2p target (the transcriptional regulator of
yeast cell wall genes, Rlm1p) (14, 22, 23).
We show, furthermore, that heat shock protein 90 (Hsp90) is
needed for ERK5 to be an active protein kinase and provide
cell integrity MAPK function in yeast. Hsp90, an essential
molecular chaperone, catalyzes the final activation step of
many key regulatory proteins in eukaryotic cells (the Hsp90
“clients”) (reviewed at http:///www.picard.ch) (41, 48).
Genomic studies with yeast have recently addressed the
breadth of the Hsp90 clientele, revealing that up to 10% of the
proteome may be subject to Hsp90 regulation (34, 63). Despite
Hsp90 being essential for many important protein kinase ac-
tivities, MAPKs are still generally considered nonclients of
Hsp90 (6, 45). We recently found, though, that the cell integ-
rity MAPK of yeast, Slt2p, is an Hsp90 client (34). In revealing
that ERK5 is also Hsp90 dependent in yeast, this investigation
provides the first evidence for a mammalian MAPK being
Hsp90 dependent, raising the issue of whether ERK5 is also an
Hsp90 client in mammals. Assuming this is the case, yeast
expressing ERK5 in place of the native Slt2p may provide a
model system in which to study how Hsp90 assists the activa-
tion of a mammalian MAPK.
MATERIALS AND METHODS
Yeast strains and yeast growth. The yeast strains used in this study are listed
in Table 1. PP30 slt2 and PP30 mkk1mkk2slt2 were constructed by hphMX4
cassette (15) deletion of the SLT2 gene in wild-type and mkk1mkk2 versions
of PP30 (44). Liquid cultures used either YP (2% [wt/vol] Bacto peptone, 1%
yeast extract, 20 mg/liter adenine) containing 2% glucose (YPD) or 3% glycerol
(YPGlycerol) or dropout glucose medium (DO) (2). Plate growth at the indi-
cated temperatures used the same media with 1.5% agar, with or without the
indicated inhibitor additions. -Factor treatment involved treating liquid YPD
cultures containing 40 mM sodium citrate, pH 4.5 (6 h 30°C), with 0.5 M
-factor (Sigma).
Expression vectors for ERK2 and ERK5 expression in yeast. Expression vec-
tors for ERK2 and ERK5 expression in yeast were constructed by PCR ampli-
fying the coding sequences of ERK2 (from plasmid pGEX4T-ERK2) (33) and
ERK5a (from image clone 4300124; GenBank accession no. BC009963) (primer
sequences available on request). TRP1 plasmid vectors (pG1-ERK2 and pG1-
ERK5, respectively), for expression of these MAPKs in yeast under the control
of the constitutive TDH1 promoter, were constructed by digesting the products
of these PCRs with BamHI plus SalI prior to their insertion into BamHI- plus
XhoI-cleaved pG1 (49). Vectors for expression of a C-terminally truncated
ERK5 (the 1 to 407 region) and also the T218A, Y220F double mutant of this
C-terminally truncated ERK5 [ERK5(1-407)(AEF)] were constructed by PCR
amplifying regions of cDNA clones previously described by Barros and Marshall
(4). These were cloned into BamHI- plus SalI-cut pUT36 (34) to generate
vectors for MET25 promoter-regulated expression of these sequences with an
N-terminal 12 His tag [pHis-ERK5(1-407) and pHis-ERK5(1-407(AEF)), re-
spectively]. The same ERK5 sequences were also cloned into PEW415 (this is
pRS415 [50] with a TPI promoter multiple-cloning site [3 hemagglutinin
{HA}] insert) (E. Hettema, unpublished) to generate plasmids for expression of
the same sequences with a C-terminal 3 HA tag [pERK5(1-407)-HA and
pERK5(1-407(AEF))-HA, respectively]. The vector for MET25 promoter-regu-
lated MKK1-P386 expression was as previously described (34).
Protein analysis. Preparation of yeast soluble protein extracts was as described
previously (40). His-ERK5(1-407) and His-ERK5(1-407(AEF)) in these extracts
TABLE 1. The yeast strains used in this study
Strain Genotype Reference
Strains with a single gene for wild-type
or T22I mutant yeast Hsp90
P82a W303-1a hsc82::LEU2 hsp82::LEU2 HIS3-HSP82a 38
T22I W303-1a hsc82::LEU2 hsp82::LEU2 HIS3-hsp82(T22I)a 38
P82aslt2 P82a slt2kanMX4 34
T22Islt2 T22I slt2kanMX4 34
PP30slt2 MATa trp1-289 leu2-3,112 his3-200 ura3-52 ade2-101oc lys2-801am
hsc82::kanMX4 hsp82::kanMX4 slt2::hphMX4 pHSC82b
This study
PP30 mkk1 mkk2 slt2 MATa trp1-289 leu2-3,112 his3-200 ura3-52 ade2-101oc lys2-801am
hsc82::kanMX4 hsp82::kanMX4 mkk1::kanMX4 mkk2::HIS3
slt2::hphMX4 pHSC82b
This study
Two-hybrid strains
PJ694a MATa trp1-901 leu2-3,112 ura3-52 his3-200 gal4 gal80 LYS2::GAL1-HIS3
GAL2-ADE2 met2::GAL7-lacZ
21
PJ694 MAT trp1-901 leu2-3,112 ura3-52 his3-200 gal4 gal80 LYS2::GAL1-HIS3
GAL2-ADE2 met2::GAL7-lacZ
21
a The only Hsp90 gene in these strains, an integrated wild-type (HSP82) or mutant (hsp82) gene expressed from the constitutive TPD1 gene promoter (38).
b The only Hsp90 gene in these strains, a wild-type HSC82 under native promoter control on a URA3 vector (44).
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was isolated by nickel-nitrilotriacetate chromatography (His-select columns; Sig-
ma); the ERK5(1-407)-HA was isolated by immunoprecipitation using anti-HA
immunoglobulin G-coated agarose beads (Sigma). Western blot analysis used the
following as primary antibodies: for MAPK detection, anti-ERK2 and anti-
ERK5 antisera (sc-5626 and sc-154, respectively; Santa Cruz); for His12-tagged
proteins, mouse His4 antibody (QIAGEN); for yeast Hsp90 and Sba1p, rabbit
polyclonal antisera raised against the latter proteins (34). The secondary anti-
body was horseradish peroxidase-conjugated anti-rabbit or anti-mouse immuno-
globulin G (Amersham) diluted 2,000-fold. Assays of MAPK activity on
ERK5(1-407)-HA immunoprecipitated from yeast cell extracts were as previ-
ously described for an HA-tagged Slt2p (24), using 50 g of ERK5(1-407)-HA
protein per assay. Where present, 1 M radicicol was added at the start of
incubation.
Two-hybrid studies. Construction of PJ694 (Table 1) expressing wild-type
and mutant forms of the Hsp82-BD fusion was described earlier (34–36). PJ694a
cells expressing either a wild-type or a nonphosphorylatable AD-ERK5 fusion
[AD-ERK5; AD-ERK5(AEF), respectively] were generated by homologous re-
combination within yeast, essentially as described previously (36, 54). These
PJ694a transformants were mated to the PJ694 strains expressing the
Hsp82-BD fusions, with the resultant PJ69-4 diploids (now expressing both the
AD and BD fusions) being selected on DO lacking histidine and tryptophan.
Automated measurement of the -galactosidase activity due to the interaction-
responsive, GAL7 promoter-regulated lacZ gene of PJ69-4 was as previously
described (34, 35). Data in Fig. 5B and C show the mean and standard deviations
(SD) of results from eight individual assays on separate aliquots of each culture.
The control diploid PJ69-4 cells contained pBDC (36) lacking a gene insert and
the plasmid for the AD fusion expression (since the low basal lacZ expression
levels in this system are generally due to the AD protein fusion, with the even
lower lacZ expression level in cells containing an Hsp82-BD “bait” and empty
AD vector [pOAD] being essentially unaffected by stress [35]).
RESULTS
Diverse slt2 mutant phenotypes are suppressed by ERK5
expression. Human ERK5 and yeast Slt2p exhibit striking se-
quence identity within their N-terminal MAPK domains
(49.7% between amino acids 32 and 357 [ERK5] and 1 and 326
[Slt2p]). Nevertheless, MAPKs are in general so extremely
conserved that this sequence identity is no more than that seen
with human ERK1/2 or with the other MAPKs of yeast. It is
within the protein kinase activation segment (defined as the
region between, and including, two conserved tripeptide motifs
[DFG. . .APE]) (39) that the primary sequence comparisons
indicate ERK5 as a possible mammalian ortholog of the yeast
Slt2p (Table 2). ERK5 and Slt2p are also set aside from the
other MAPKs of humans and yeast, respectively, by virtue of
unusually large sequence extensions C-terminal to the MAPK
domain. These C-terminal regions are important for certain of
the events of transcription factor activation by ERK5 in hu-
mans and by Slt2p in yeast (see Discussion).
Initially, we sought to test whether ERK5 expression would
suppress the effects of Slt2p loss in yeast (phenotypes of the
slt2 mutant). The mouse erk5 gene spans 	5.6 kb and com-
prises 6 exons and 5 introns. Alternative splicing of its tran-
scripts generates three ERK5 isoforms, a, b, and c, but of
these, only ERK5a is an active kinase (60). It was therefore the
human equivalent of this ERK5a that we expressed (together
with ERK2) in yeast. The expression vector pG1-ERK2 or
pG1-ERK5 (see Materials and Methods) was found to lead to
the synthesis of proteins recognized by anti-ERK2 or anti-
ERK5 antisera, respectively (Fig. 1A and B).
Early studies revealed a number of phenotypes generated by
Slt2p loss in yeast, including temperature and caffeine sensi-
tivity (24, 27, 32), as well as an inability to form mating pro-
jections in response to the pheromone -factor (62). To see
whether ERK2 or ERK5 expression would rescue these de-
fects, pG1-ERK2, pG1-ERK5, and the empty vector lacking
any gene insert (pG1) were transformed into P82a and
P82aslt2 (Table 1), strains isogenic but for the presence or
absence of the SLT2 gene. pG1-ERK5, but not pG1-ERK2,
restored caffeine resistance and a capacity for high-tempera-
ture growth in the P82aslt2 mutant (Fig. 1C). Other slt2
mutant phenotypes were also suppressed by this ERK5 expres-
sion (but not the ERK2 expression), including the lack of
growth on respiratory carbon sources (57); sensitivities to com-
pounds that affect the cell wall, such as calcofluor white (9, 28)
and hygromycin B (8); and sensitivities to rapamycin and hy-
droxyurea (29, 47) (Fig. 1D). ERK5 expression also restored to
slt2 cells the capacity to form mating projections in response
to mating pheromone -factor (Fig. 1E). ERK5 expression
rescuing such a diverse spectrum of slt2 mutant phenotypes
revealed that this expression is providing many, if not all, of the
functions of the native Slt2p cell integrity MAPK in yeast.
Expressed in yeast in place of the native Slt2p, ERK5 stim-
ulates a native Slt2p target, the Rlm1p transcriptional regu-
lator of cell wall genes. In its active, dually Thr/Tyr-phosphor-
ylated state, the yeast cell integrity MAPK binds to its
recognition (docking) domains on both substrates (targets of
Slt2p-mediated phosphorylation) and the protein phosphatases
that will eventually restore this Slt2p to the state of an inacti-
vated MAPK (7, 12, 16). In the cytosol, this active Slt2p is
recruited to the cell cortex (55), while in the nucleus, it acti-
vates two transcription factor regulators of cell integrity genes,
Rlm1p and Swi4p (30). Rlm1p appears to be the major trans-
activator of cell wall genes in yeast (14, 22, 23).
slt2 mutant cells exhibit a pronounced Rlm1p activity de-
fect (58). To determine if the expression of ERK5 was rescuing
this defect, a reporter gene of Rlm1p activity (YIL117c-lacZ)
(23) was monitored in SLT2 (strain P82a) and slt2 (strain
P82aslt2) cells containing either pG1 or pG1-ERK5. Rlm1p
activity was substantially restored to the slt2 mutant by the
presence of the pG1-ERK5 expression vector, with the levels
of this activity being increased with two stresses that stimulate
cell integrity signaling (heat shock and caffeine) (Fig. 2A).
Activity of ERK5 in yeast requires the MAP2K of the cell
integrity pathway. Slt2p, the MAPK functionally comple-
mented by this ERK5 expression in yeast, is part a signaling
cascade composed of a MAP3K (Bck1p), a pair of redundant
TABLE 2. Alignment of the activation loop regions of the five
yeast MAPKs, human ERK5, and human ERK2
MAPK Sequencea
Kss1p..................DFGLARCLASSSDSRETLVG–––FMTEYVATRWYRAPE
Fus3p .................DFGLARIIDESAADNSEPTGQQSGMTEYVATRWYRAPE
Smk1p ................DFGLARGIHAGFFKCHSTVQP––HITNYVATRWYRAPE
Hog1p ................DFGLARIQDPQ–––––––––––––MTGYVSTRYYRAPE
Slt2p ...................DFGLARGYSENPVENSQ––––––FLTEYVATRWYRAPE
ERK5 .................DFGMARGLCTSPAEHQY––––––FMTEYVATRWYRAPE
ERK2 .................DFGLARVADPDHDHTG–––––––FLTEYVATRWYRAPE
Identityb .............***:** :* **:**:*****
a A G. . . .P. . .E motif common to Slt2p and ERK5 is in boldface type; the
TXY motif that is dually Thr/Tyr phosphorylated by the activating MAP2K is
underlined.
b A highly flexible loop anchored between conserved DFG and APE tripeptide
sequences in protein kinases (39).
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MAP2Ks (Mkk1/2p), and Slt2p (reviewed in reference 30). To
confirm that ERK5 was becoming activated in yeast by this cell
integrity cascade (i.e., by the MAP2K Mkk1/2p), both a full-
length ERK5 and a C-terminally truncated ERK5 [ERK5(1-
407)] (the latter a form partially functional in vivo; see below)
were expressed in a slt2 mkk1 mkk2 triple-mutant strain
(Table 1). As with the slt2 single mutant, this triple mutant
displays the characteristic phenotypes of loss of Slt2p-mediated
FIG. 1. ERK5 expression complements loss of Slt2p function in yeast. (A and B) Protein extracts from strain P82a transformed with pG1,
pG1-ERK2, or pG1-ERK5, analyzed by Western blotting using anti-ERK2 (A) or anti-ERK5 (B) antisera. Sba1p was used as a loading control.
(C) Comparison of 3-day YPD growth either at 37°C or at 30°C with or without caffeine for wild type (WT; strain P82a) cells transformed with
pG1 as well as P82aslt2 transformed with pG1, pG1-ERK2, or pG1-ERK5. (D) Growth (3 days, 30°C) of P82aslt2 transformed with pG1 or
pG1-ERK5 on glycerol, a respiratory carbon source, or on YPD without or containing 50 g ml
1 calcofluor white (CFW), 50 g ml
1 hygromycin
B (HygB), 160 mM or 200 mM hydroxyurea (HU), or 5 ng ml
1 rapamycin. (E) Analysis of the formation of mating pheromone projections in
P82aslt2 transformed with either pG1 or pG1-ERK5.
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signaling. Whereas ERK5 expression could suppress these
phenotypes when the signaling components of the cell integrity
pathway upstream of Slt2p were still intact (slt2 cells) (Fig.
1C to E; Fig. 3A), it was unable to rescue these phenotypes in
this slt2 mkk1 mkk2 triple-mutant background (the lack of
any rescue of high-temperature growth or Rlm1p activity is
shown in Fig. 2B and C). Therefore, ERK5 becomes activated
in yeast by the MAP2K of the cell integrity cascade.
Activity of ERK5 in yeast cell extracts is abolished with the
loss of Mkk1/2p and with Hsp90 inhibitor treatment. Our
initial attempts to demonstrate ERK5 activity in yeast by stan-
dard MAPK assay were thwarted by an inability to obtain the
full-length ERK5 in soluble form in cell extracts. Such prob-
lems may have been caused by the known oligomerization
properties of ERK5 (56). We had previously found, though,
that in the case of the native Slt2p, the in vitro MAPK activity
FIG. 2. ERK5 restores Rlm1p activity in the slt2 mutant, with activity rescue abolished by the expression of a T22I mutant Hsp90 or the loss of
Mkk1/2p. (A) Expression of a YIL117c-lacZ reporter of Rlm1p activity in strains P82a, P82aslt2, T22I, and T22Islt2, either containing empty pG1
vector (E) or the pG1-ERK5 expression vector (ERK5). (B and C) Analysis of 37°C growth (B) and Rlm1p activity (C) in a slt2 mkk1 mkk2 triple
mutant transformed with either empty pG1 (E) or pG1-ERK5 (ERK5) compared to the PP30 parent strain (WT). YIL117c-lacZ expression measure-
ments were on cells either in growth at 25°C (unstressed), heat shocked from 25°C to 37°C for 1 h, or exposed to 8 mM caffeine for 1 h at 25°C.
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is preserved in a C-terminally truncated, dually TEY-phosphor-
ylated protein that comprises just the N-terminal MAPK do-
main (34; also unpublished data). By expressing in the yeast a
C-terminally truncated, HA-tagged ERK5 [ERK5(1-407)-HA]
(see Materials and Methods), the solubility problems experi-
enced with the full-length ERK5 were overcome. As with the
corresponding C-terminally truncated form of Slt2p (28, 51),
ERK5(1-407)-HA is partially functional in vivo, rescuing
Swi4p-dependent, but not Rlm1p-dependent, transcription of
slt2 cells. Thus, when expressed in slt2 cells, this ERK5(1-
407)-HA is able to rescue the growth at high temperatures and
on respiratory medium but not the caffeine sensitivity or the
lack of mating projection formation (Fig. 3A; also data not
shown).
ERK5(1-407)-HA was immunoprecipitated from extracts of
slt2 single-mutant and slt2mkk1mkk2 triple-mutant cells
and assayed for MAPK activity (Fig. 3B). The activity of the
ERK5(1-407)-HA expressed in slt2 cells was increased by
heat shock of the cells prior to extract preparation (a stress that
activates cell integrity signaling) (Fig. 3B). Importantly, this
activity from slt2 cells was inhibited by the presence of the
highly selective Hsp90 inhibitor radicicol (Fig. 3B), revealing
ERK5(1-407)-HA to be an Hsp90-dependent protein kinase
(the native yeast Slt2p cell integrity MAPK is also an Hsp90
client) (34). There was no ERK5(1-407)-HA activity in the
extracts from the slt2 mkk1 mkk2 triple mutant (Fig. 3B),
consistent with this MAPK being activated by the MAP2K of
the cell integrity pathway.
Expression of T22I mutant Hsp90 abolishes ERK5 activity
in yeast. T22I (Table 1) is a yeast mutant that expresses a T22I
point mutant form of Hsp90 as its sole form of Hsp90 chap-
erone (38). This strain is defective in the maintenance of cell
integrity, displaying a phenotype similar to that of mutants
defective in cell integrity pathway signaling (34). T22I exhibits
Mkk1/2-directed phosphorylation of Slt2p in response to the
activation of cell integrity signaling, but its defect in Hsp90
prevents this phosphorylated Slt2p from activating Rlm1p (34)
(Fig. 2A).
Strains lacking the endogenous Slt2p MAPK and expressing
either a wild-type or a T22I mutant Hsp90 (P82aslt2 and
T22Islt2, respectively) (Table 1) were transformed with pG1-
ERK5 and the control empty vector (pG1). ERK5 expression
restored both high-temperature growth and caffeine resistance
to the slt2 cells containing the wild-type Hsp90 but provided
no such rescue in the cells isogenic but for their possession of
T22I mutant Hsp90 (compare P82aslt2 and T22Islt2) (Fig.
4A and B). ERK5 rescue of the Rlm1p activity in the slt2
mutant was similarly abolished by this T22I mutation in Hsp90
(compare the Rlm1p activity data of P82aslt2 and T22Islt2)
(Fig. 2A).
Excessively high MAPK activity levels are generally ex-
tremely detrimental for yeast (16, 57, 58). Such an effect is seen
FIG. 3. Analysis of a C-terminally truncated ERK5 expressed in yeast. (A) Expression of a MET25 promoter-regulated ERK5(1-407)-HA
restores high temperature growth, but not caffeine resistance, in the slt2 mutant. Wild-type (WT, strain p82a) and P82aslt2 (slt2) cells
containing either empty PEW415 vector (E), pERK5(1-407)-HA, or pERK5(1-407(AEF))-HA were grown for 3 days at the indicated temperature
on DO medium lacking uracil and methionine. (B) Phosphorylation of myelin basic protein (MBP) by the ERK5(1-407)-HA immunoprecipitated
from extracts of unstressed or heat-shocked (1 h at 37°C) slt2 single-mutant and slt2 mkk1 mkk2 triple-mutant cells. Immunoprecipitated
fractions were also Western blotted and probed with anti-HA antiserum.
VOL. 5, 2006 HUMAN ERK5 IS AN Hsp90 CLIENT IN YEAST 1919
with the expression of MKK1-P386, the gene for an overactive
point mutant form of Mkk1p cell integrity MAP2K (57). The
toxicity of this MKK1-P386 is, in turn, suppressed by defects in
either Slt2p or Rlm1p (57). As shown in Fig. 4B, MKK1-P386
expression exerted a strong dominant-negative effect on the
growth of ERK5-expressing, Slt2p-deficient cells containing
the wild-type Hsp90 (P82aslt2). This effect was, though, ab-
sent in cells isogenic but for their expression of the T22I mu-
tant form of Hsp90 (T22Islt2) (Fig. 4B). Replacement of
wild-type Hsp90 by this T22I mutant Hsp90 also abolishes the
toxicity of MKK1-P386 in cells with the native Slt2p (34).
Therefore, the high cell integrity MAPK activity (ERK5 or
Slt2p) that is normally generated by MKK1-P386P in vivo is
abolished by the T22I mutation in Hsp90. T22I mutant cells
display essentially normal Slt2p MAPK phosphorylation in re-
sponse to the activation of cell integrity signaling (34). Their
partially compromised Hsp90 activity, though, acts to prevent
the in vivo activation of Rlm1p (34) by this phosphorylated
Slt2p (34) or the heterologously expressed ERK5 (Fig. 2A).
Strong Hsp90 association is selective for the dually TEY-
phosphorylated state of ERK5. Through protein binding stud-
ies, using wild-type and mutant forms of both Hsp90 and Slt2p,
and also a study of the two-hybrid interaction of the corre-
sponding wild-type and mutant forms of Hsp90-Gal4p DNA
binding domain (Hsp82-BD) and Gal4p activator domain
(AD) Slt2p fusions, we recently demonstrated that Hsp90
binding is selective for the dually Tyr,Thr-phosphorylated state
of Slt2p (34). This was the first study to show that an Hsp90
client can acquire its capacity to bind Hsp90 through regula-
tory phosphorylation. It indicates that phosphorylation of Slt2p
by the upstream Mkk1/2p MAP2K leads to the creation of an
Hsp90-binding surface on this MAPK. In vivo Hsp90-Slt2p
interaction is therefore strengthened with stimulation of cell
integrity signaling and, therefore, increases in Mkk1/2p activ-
ity. Upon finding that ERK5 expression would rescue many of
the effects of loss of this Slt2p in vivo (Fig. 1), we investigated
whether ERK5 would also bind Hsp90 and whether such bind-
ing is affected by the loss of activating Tyr,Thr phosphorylation
of ERK5.
A His-tagged, C-terminally truncated ERK5 was expressed
in slt2 yeast both in native [His-ERK5(1-407)] and nonphos-
phorylatable T218A,Y220F double-mutant [His-ERK5(1-
407(AEF)] form (see Materials and Methods). The His-
ERK5(1-407) present in extracts of these cells was found to be
associated with appreciable amounts of Hsp90, with this Hsp90
binding being increased under conditions of heat or caffeine
stress (Fig. 5A). In contrast, the nonphosphorylatable His-
ERK5(1-407(AEF)) exhibited only weak Hsp90 binding, irre-
FIG. 4. An Hsp90 mutation compromises ERK5 activity in yeast. (A) Growth at 37°C and caffeine resistance of P82a and T22I, strains
expressing wild-type or T22I mutant Hsp90, and Slt2p-deficient forms of these strains (P82aslt2 and T22Islt2) transformed with either the
pG1-ERK5 expression vector (ERK5) or the control pG1 (E). (B) MET25 promoter-regulated MKK1-P386 expression exerts a dominant-negative
effect in ERK5-expressing cells with the wild-type Hsp90 (P82aslt2) but not those with T22I mutant Hsp90 (T22Islt2). Growth (3 days, 30°C)
was on DO medium either lacking only uracil or lacking uracil and methionine.
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spective of whether the cells had been stressed prior to extract
preparation (Fig. 5A). These findings indicated that Mkk1/2p-
directed phosphorylation of ERK5 is a requirement for strong
Hsp90 binding by this MAPK in cell extracts.
To confirm that the dual phosphorylation of ERK5 is also a
prerequisite for Hsp90 binding to this MAPK in vivo, yeasts
expressing the Hsp82-BD “bait” fusion and either a wild-type
(AD-ERK5) or a nonphosphorylatable [AD-ERK5(AEF)]
FIG. 5. Strong Hsp90 binding is selective for the phosphorylated state of ERK5. (A) Levels of Hsp90 associated with nickel resin-retained, wild-type
or nonphosphorylatable AEF mutant His-ERK5(1-407). Extracts were from cultures of P82aslt2 mutant cells expressing these His-ERK5(1-407) forms
either in growth at 25°C, heat shocked from 25 to 39°C for 1 h, or treated with 8 mM caffeine for 1 h at 25°C, The control lane (C) is the extract from
unstressed, non-ERK5-expressing P82aslt2. (B) Two-hybrid interaction of a functional Hsp82-BD bait with the control (pBDC), wild type (AD-ERK5),
or nonphosphorylatable [AD-ERK5(AEF)] prey fusions in cultures either unstressed, heat shocked, or caffeine treated as for panel A, showing that
Hsp90-ERK5 interaction is moderately strengthened by stress and selective for the phosphorylatable form of the MAPK. (C) Effects of the E33A and
D79N mutations in the Hsp82-BD bait fusion on two-hybrid interaction with AD-ERK5. The control cells (pBDC) contained wild-type AD-ERK5
together with the empty pBDC vector, since the basal lacZ expression in this system is mainly due to the AD fusion (35).
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“prey” fusion were generated for two-hybrid purposes (see
Materials and Methods). The former fusion is substantially a
functional form of Hsp90 in vivo (36). These yeast strains were
then used to determine the relative strengths of basal and
stress-induced Hsp82-BD–AD-ERK5 interaction. Figures 5B
and C show these interaction measurements, determined from
levels of expression of the interaction-responsive, GAL7 pro-
moter-regulated lacZ gene of the two-hybrid strain (34, 35). As
with the corresponding two-hybrid interaction of AD-Slt2p
with this same Hsp90 bait (Hsp82-BD–AD-Slt2p) (34),
Hsp82-BD exhibited a stress-reinforced in vivo interaction with
the native AD-ERK5 “prey” fusion, while mutations that pre-
vent phosphorylation of this fusion [the double-mutant form,
AD-ERK5(AEF)] substantially abolished this Hsp82-BD–AD-
ERK5 interaction (Fig. 5B).
The Hsp82-BD–AD-ERK5 two-hybrid interaction was con-
siderably reinforced by the presence of the E33A mutation in
the Hsp82-BD fusion [Hsp82(E33A)-BD] (Fig. 5C). E33A is
an Hsp90 mutation that arrests the Hsp90 chaperone cycle,
allowing this cycle to progress to a late-stage complex where
the client protein is stabilized in tight association with the
ATP-bound state of Hsp90 but where the final ATPase-depen-
dent release of the activated client from the chaperone com-
plex is blocked (40). In contrast, two-hybrid Hsp82-BD–AD-
ERK5 interaction was abolished by the D79N mutation in the
Hsp82-BD fusion [Hsp82(D79N)-BD] (Fig. 5C), a mutation
that prevents ADP/ATP binding to Hsp90 (40).
Taken together, the data in Fig. 5 reveal that, as for the
native Slt2p MAPK (34), it is the dually Tyr/Thr-phosphory-
lated form of ERK5 that engages in a strong association with
the Hsp90 chaperone. Furthermore, when the chaperone cycle
is inhibited by the E33A mutation in Hsp90, a late-stage chap-
erone cycle complex accumulates in vivo that comprises this
phosphorylated ERK5 in association with the mutant Hsp90
(Fig. 5C). Such physical interaction of Hsp90 with the phos-
phorylated ERK5 (Fig. 5) is almost certainly a key step in
Hsp90 activation of this MAPK (Fig. 3B and 4).
DISCUSSION
This study reveals that an expression of human ERK5 res-
cues many of the phenotypes resulting from the loss of the
native Slt2p MAPK in slt2 yeast (Fig. 1). ERK5 can confer
cell integrity MAPK function in yeast, as it is capable both of
being activated by the cell integrity signaling pathway and, in
its activated state, stimulating transcription factor targets of
Slt2p (Rlm1p [Fig. 2 and 3] and Swi4p [data not shown]). We
show, furthermore, that ERK5 expressed in yeast is a client of
the Hsp90 chaperone system, the first evidence of Hsp90 de-
pendence for a true mammalian MAPK. Hsp90 binding has
been shown to stabilize Mok1p, a mammalian protein kinase
moderately related structurally to the conventional MAPKs
(37). A number of the kinases of various MAPK signaling
cascades are also known to be Hsp90 dependent (6, 31, 45, 53).
In these cascades, it appears that several MAP3Ks are Hsp90
clients (see reference 6 for literature). In contrast, the
MAP2Ks and MAPKs are generally nonclients (6), though
there appear to be some exceptions to this rule (e.g., Wis1p, an
MAP2K of Schizosaccharomyces pombe [53] and the Slt2p/
ERK5 MAPKs that we have been studying). To date, assigna-
tions of Hsp90 client status to mammalian protein kinases have
generally been based on identifying those kinases that become
destabilized when cells are treated with Hsp90 inhibitor drugs
(6, 46). In such a screen, ERK5 is not destabilized and is
therefore not designated an Hsp90 client (6). This lack of
destabilization with Hsp90 inhibitor drug treatment might,
though, merely reflect much of the ERK5 in cells not being in
its MAP2K-phosphorylated state. Our findings (Fig. 5) indi-
cate that only the Mkk1/2p-phosphorylated form of ERK5 is in
strong association with Hsp90, at least in the yeast system.
This study and our earlier investigation of the Slt2p-Hsp90
interaction (34) are the first to show that Hsp90 clients can be
rendered Hsp90 binding as the result of regulatory phosphor-
ylation. Slt2p and ERK5 both become strong Hsp90-binding
agents upon Mkk1/2p-catalyzed dual Thr/Tyr phosphorylation
of the TEY motif in their activation loop (Table 2; Fig. 5).
These phosphorylations, at sites in close proximity to the com-
mon Hsp90-binding surface recently identified on a number of
protein kinases (6), may cause localized structural rearrange-
ment of this region, leading to the creation of the Hsp90-
binding surface on Slt2p and ERK5. Alternatively, displace-
ment of the activating MAP2K may uncover such a surface.
ERK5 expression complementing the mutational defects of
slt2 yeast provides a model experimental system for investi-
gating ERK5 activity. It can be used to analyze the Hsp90
dependence of a mammalian MAPK. Also, the strong suppres-
sion of several slt2 mutant phenotypes through ERK5 expres-
sion (Fig. 1) might be used to screen for ERK5 inhibitors. In
addition, it should allow screens for constitutively active, gain-
of-function (GOF) and dominant-negative mutant forms of
ERK5. Once isolated, these mutant forms can then be trans-
ferred to mammalian cells for an analysis of the effects of
altered ERK5 activity in a variety of cell culture systems. The
utility of yeast for direct selection of such MAPK mutations is
already very well established, e.g., Fus3p (see reference 11 for
literature) and Hog1p (59). In contrast, it has proven much
more difficult to isolate mutant MAPKs using mammalian cul-
ture systems, even though GOF mutations in the mammalian
MAPKs can be associated with malignancy (20). Indeed, the
only successful engineering of mammalian MAPKs for GOF to
date appears to have been by the introduction of mutations
originally identified for yeast Fus3p into rat ERK2 (all at
residues precisely conserved between Fus3p and ERK2) (11).
Such studies reveal just how valuable yeast screens for altered
MAPK activity can be when attempting to engineer the mam-
malian MAPKs.
A shared property of the two MAPKs so far shown to be
Hsp90 dependent (ERK5 [this study] and yeast Slt2p [34]) is
that they stimulate MADS (MCM1, agamous deficiens serum
response factor) box transcription factors, with these being
among their best-characterized substrates. In mammals, ERK5
regulates the myocyte enhancer factor (MEF) family of tran-
scriptional regulators (MEF2A, C, and D), with direct ERK5
phosphorylation of MEF2C acting to increase the transcrip-
tional activity of the latter and, therefore, c-jun expression
(26). In yeast, the MADS box transcription factor Rlm1p is
similarly activated through direct, in this case Slt2p-mediated,
phosphorylation (23). Remarkably, yeast Rlm1p shares with
the mammalian MEF2s the same in vitro DNA binding spec-
ificity [CTA(T/A)4TAG] (10) and MAPK docking domain se-
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quence (residues 324 to 329 in Rlm1p [23] and 273 to 278 in
MEF2A [61]). The N-terminal kinase domains of ERK5 and
Slt2p are, though, not the only regions of these MAPKs that
interact with MADS box transcription factors. Loss of se-
quences C-terminal to the MAPK domain on these MAPKs,
though it does not prevent in vitro MAPK activity (Fig. 3B),
prevents in vivo activation of MEF2 (60) or Rlm1p (our un-
published data) by ERK5 or Slt2p, respectively. Within this
C-terminal tail region on ERK5 is a MEF2-interacting region
(residues 440 to 501) and transcriptional activation domain
(residues 664 to 789) (25, 61). The C-terminal tail of Slt2p also
has transcriptional activation potential (28, 51). Therefore, the
C-terminal sequence extensions that set ERK5 and Slt2p apart
from the other MAPKs of mammalian cells and yeast appear
to be of rather similar function. This, in turn, probably con-
tributes to the ability of ERK5 to provide cell integrity MAPK
function when expressed in yeast in place of the native Slt2p
(Fig. 1). Despite this, these C-terminal regions display no ob-
vious sequence similarities. That of Slt2p is much smaller
(Slt2p is only 484 amino acids long, whereas ERK5 is 789
amino acids). Also, it has no MAPK phosphorylation consen-
sus, whereas the much larger C-terminal region of ERK5 con-
tains no less than 10 potential MAPK phosphorylation sites
(ERK5 undergoes autophosphorylation) (5) and 2 proline-rich
regions. The second of these ERK5 proline-rich regions (124
amino acids with 44 prolines) includes several proline-alanine
repeats, a motif also present in myosin light chain kinase,
where it interacts directly with actin. Thus, like the nuclear
localization signal of the ERK5 C-terminal tail (5, 60), this
region may have a role in the targeting of ERK5 to specific
locations in the cell (60).
Hsp90 dependence may be limited to just a few MAPKs.
Whether the Hsp90 requirement of ERK5 and Slt2p is asso-
ciated with the role of the large C-terminal sequence regions
on these MAPKs is at present unclear, although loss of the
latter region on ERK5 does not abolish either Hsp90 binding
(34) (Fig. 5A) or the susceptibility of the kinase activity to
Hsp90 inhibitors (Fig. 3B).
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